India pharma exports to touch $20 billion by 2020: Study


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Indian pharmaceutical exports are likely to touch $20 billion by 2020 from the current level of around $16.5 billion, registering a compounded annual growth rate (CAGR) of about 30 percent.

Indian pharmaceutical exports are likely to touch $20 billion by 2020 from the current level of around $16.5 billion, registering a compounded annual growth rate (CAGR) of about 30 per cent, says a joint study by Assocham and UL India.

Indian pharmaceutical sector is expected to register a growth of about 16 per cent in 2018 and is likely to touch $55 billion by 2020 from the current level of $28 billion, the study.

Most of the exports, says the Assocham Secretary General D S Rawat, shall be derived from generic drugs.

India is the third-largest global generic Active Pharmaceutical Ingredient (API) manufacturer in terms of market share and generic drugs form the largest segment of the Indian pharmaceutical sector and today.

India is easily the largest provider of generic medicines globally by volume. Current projections show that as India continues to develop this sector, its growth will expand in the next several years.

India accounts for the second largest number of Abbreviated New Drug Applications (ANDAs) and is the world’s leader in Drug Master Files (DMFs) applications with the US, adds the study.

India has 24,000 pharmaceutical companies, 250 of which are in the organised category. These 250 organised companies control nearly 70 per cent of the market.

About 8,000 small-scale units together form the core of the pharmaceutical industry in India, including five Central Public Sector Units.

Since many of the highly profitable drugs shall be going off patent in the coming years, this will benefit the companies in India who can now manufacture these drugs and enable them to capture more revenues.

They will be generating profits to become innovative companies which will enable them to evolve out of generic manufacturing to grow, develop and market their own pharmaceuticals through robust R&D which will allow them to expand globally.

To fully make the transition from a local generics drugs provider to become a global quality standard, manufacturers must look at different business models whilst at the same time considering the increasingly complex regulatory environment.

Partnering with experts in all scientific, technical and especially regulatory fields can reduce overheads and ensure the best guidance on approaches to maximize on the investment made.

The industry need to collaborate with internal and external customers to identify Critical to Quality parameters to improve internal processes and ensure patient safety, while building relationships with key stakeholders one should solicit feedback.

This effort recognises impact it has on product quality upon implementation, and all quality related data that includes recalls, adverse event reports, warning letters etc is now available on open.fda.gov.

Under the right for information act, one regulatory agency is liable to share a company’s final audit report with another regulatory agency without seeking their approval.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026